Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.

Abstract

BACKGROUND:

Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated.

METHODS:

African children vaccinated at 12-23 months of age with PsA-TT were followed for evaluation of antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring group A serum bactericidal antibody (SBA) with rabbit complement and by a group A-specific IgG enzyme-linked immunosorbent assay (ELISA).

RESULTS:

Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccination and plateaued at levels significantly above baseline for up to 5 years following primary vaccination.

CONCLUSIONS:

A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccination.

CLINICAL TRIALS REGISTRATION:

ISRTCN78147026.

• Authors: Milagritos D Tapia, Helen Findlow, Olubukola T Idoko, Marie-Pierre Preziosi, Prasad S Kulkarni, Godwin C Enwere, Cheryl Elie, Varsha Parulekar, Samba O Sow, Fadima Cheick Haidara, Fatoumata Diallo, Moussa Doumbia, Adebayo K Akinsola, Richard A Adegbola, Beate Kampmann, Julie Chaumont, Lionel Martellet, Elisa Marchetti, Simonetta Viviani, Yuxiao Tang, Brian D Plikaytis, F Marc LaForce, George Carlone, Ray Borrow
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 61 Suppl 5 Pg. S514-20 (Nov 15 2015) ISSN: 1537-6591 [Electronic] United States
• PMID: 26553683 (Publication Type: Clinical Trial, Journal Article)
• Copyright: © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

Chemical References

• Antibodies, Bacterial
• Immunoglobulin G
• MenAfriVac
• Meningococcal Vaccines
• Complement System Proteins

Topics

• Africa
• Animals
• Antibodies, Bacterial (blood)
• Blood Bactericidal Activity
• Complement System Proteins
• Enzyme-Linked Immunosorbent Assay
• Female
• Follow-Up Studies
• Humans
• Immunoglobulin G (blood)
• Infant
• Male
• Meningococcal Vaccines (administration & dosage, immunology)
• Rabbits
• Time Factors